Our study found that low-risk patients had a lower tumor purity and benefited more from PD-1 and CTLA-4 antibodies, providing a theoretical foundation for the clinical application of ICI (Figures 5A, 5B, 8A–8D). The gene discussed is PDCD1; the disease is neoplasm.